Drug intelligence / Profile preview

FCN-307

Development stage: Preclinical
Lead developer: Fochon Biosciences
Modality: Small Molecules

Overview

FCN-307 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, currently under development by Chongqing Fochon Pharmaceutical for the treatment of gout. URAT1, encoded by the SLC22A12 gene, is a renal transporter responsible for the reabsorption of filtered uric acid from the proximal tubules back into the blood. By inhibiting URAT1, FCN-307 increases the renal excretion of uric acid, thereby lowering serum urate levels in patients with hyperuricemia. The drug is currently in the IND-enabling phase of development, targeting the underlying metabolic cause of gout by promoting urate excretion.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on FCN-307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-307.

Explore the full profile